Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metoprolol for CRS in CAR T-Cell Therapy
NCT04082910Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of metoprolol in cytokine release syndrome (CRS) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Safety and tolerability of metoprolol. Status: unknown.
02
Drugs
metoprolol
03
Conditions
cytokine release syndrome (CRS)
Beyond the preview
Go deeper on NCT04082910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082910.